Why This Landed on My Radar
If you’ve been prescribing GLP-1s - and honestly, who hasn’t at this point - you’ve probably noticed the landscape shifting fast. The virtual clinics that made their name on easy semaglutide access are now scrambling to add “holistic programs” because the commodity play is already compressing margins. What caught my eye here is the argument that even those add-ons aren’t enough, and that we’re about to see a real separation between practices that treat GLP-1s as prescriptions versus those that treat them as the entry point to genuine metabolic optimization.
Here’s What’s Going On
The virtual clinic GLP-1 boom is essentially over as a differentiated business model. Companies like Ro, hims & hers, Calibrate, and Found built their growth on speed and access - get patients on tirzepatide or semaglutide fast, undercut traditional care on price and convenience. But that’s now table stakes, and their margins are showing it. The next move for these platforms has been to layer on coaching, continuous glucose monitors, and behavioral support to create “holistic” programs.
The problem, according to industry observers, is that holistic without personalization is just a better feature set, not a sustainable advantage. Most of these programs are still built for the average patient, which means they’re not really optimized for anyone in particular. The argument being made is that the real competitive moat going forward will be biology-based personalization - using a patient’s actual phenotype, biomarkers, and physiology to design individualized regimens rather than plugging everyone into the same program with minor tweaks.
The science and tools to do this already exist. What’s missing is the incentive for most players to move beyond the current land-grab phase and invest in true precision medicine approaches.
What This Means for Your Practice
This matters for us because we’re sitting at a critical inflection point with GLP-1 demand, and how we respond will determine whether this becomes a revenue opportunity or a referral leak. Texas patients are already seeking these medications - many are going to virtual clinics because we haven’t built a compelling in-practice pathway. And with no Medicaid expansion, we’ve got a large cash-pay and underinsured population that’s particularly vulnerable to being siphoned off by direct-to-consumer platforms.
But here’s the opportunity: independent practices are actually better positioned than virtual clinics to deliver what comes next. We already know our patients. We have their labs, their history, their comorbidities. We can see them in person when needed. What we’ve been missing is the systematic approach to turn GLP-1 prescribing into comprehensive metabolic management.
Think about your panel right now. You’ve got patients on semaglutide who are losing weight but feeling exhausted. Patients on tirzepatide with great A1Cs but persistent inflammation markers. Patients asking about switching to retatrutide based on something they read online. If your only offer is “here’s your refill,” you’re not delivering value that justifies keeping care in your practice versus a $199/month virtual clinic.
The practices that will win here are those that build a real metabolic optimization program - baseline comprehensive labs, phenotype-specific titration protocols, ongoing biomarker tracking, nutrition and lifestyle integration that’s actually personalized to the patient’s labs and response patterns. This isn’t rocket science, but it does require systems. For MA patients especially, where V28 makes HCC capture more valuable than ever, managing GLP-1 patients with proper documentation of their metabolic improvements, complications, and comorbidities becomes both better care and better revenue.
In major Texas metros, you’re competing with well-funded obesity medicine clinics and virtual platforms. In rural areas, you might be the only realistic option for ongoing management. Either way, the question is whether you’re going to own this patient relationship or just be the prior authorization signer.
Key Takeaways
- GLP-1 prescribing alone is already commoditized - virtual clinics proved the low-touch model works, which means competing on that basis is a race to the bottom
- The next differentiation is personalization - using actual biomarkers and phenotype to guide medication choice, titration, and adjunctive interventions
- You already have the relationship advantage - you know your patients’ history and can see them in person, but you need systems to leverage that into comprehensive metabolic management
- The cash-pay opportunity is real in Texas - with our uninsured population and spotty MA coverage for newer agents, building a structured patient-pay metabolic program could be meaningful revenue
- Document everything for your MA patients - proper HCC capture for obesity, diabetes, metabolic syndrome, and GLP-1 complications matters more under V28
What Smart Practices Are Doing
The practices getting ahead of this are building structured metabolic health programs with baseline comprehensive metabolic panels, body composition analysis, and regular biomarker monitoring tied to medication adjustments. They’re training staff to manage the workflow and using the GLP-1 patient as an entry point for deeper primary care engagement - not a one-off prescription factory.
Source
“Your GLP-1 Prescription Is Table Stakes. Now What?” - HIT Consultant
Primary Care Perspective delivers curated intelligence from trusted healthcare sources.
© 2026 Primary Care Perspective | Texas Edition